BCHU announces change to time interval between two doses of COVID-19 vaccine

Published on: March 11, 2021

BRANTFORD, ON – The Brant County Health Unit (BCHU) will be rebooking COVID-19 vaccine appointment times for all residents who currently have a second dose appointment booked. Second dose appointments will now be booked 16 weeks after the first dose has been administered. Affected residents will be contacted by BCHU to inform them of this change and to advise of the next steps to booking a new second appointment.

This announcement comes following direction from the Province that all those administering COVID-19 vaccine begin to follow recommendations made by the National Advisory Committee on Immunization (NACI) to extend the time interval between the first and second doses of the current, Health Canada approved, two dose COVID-19 vaccines to 16 weeks.

As a result of this decision, public health units across Ontario have been directed to make adjustments to pre-existing second dose appointments for those that do not fall within the new 16 week second dose interval.  This will allow Ontario to rapidly accelerate its vaccine rollout and maximize the number of people receiving a first dose within a context of limited supply.

As per guidance from the Province, the following populations will not have their second dose interval extended to the 16 week interval:

  • Residents of long-term care homes, retirement homes, Elder Care Lodges and Assisted Living facilities who are at the greatest risk of both exposure to COVID-19 and serious illness and death; and
  • Remote and isolated First Nation communities

Within the next two weeks, all those making first dose appointments will be able to book second appointments 16 weeks from when they receive their first dose.  

To learn more about COVID-19, how you can protect yourself and what to do if you suspect you may be at risk, please visit www.bchu.org/coronavirus or visit Ontario’s website to learn more about how the Province continues to protect Ontarians from COVID-19.